Article Text

Download PDFPDF
Variations in access to continuous glucose monitoring and flash glucose sensors for children and young people in England and Wales: a national survey
  1. Elspeth Clare Ferguson1,
  2. Neil Wright1,
  3. Fiona Regan2,
  4. Juliana Chizo Agwu3,4,
  5. Eleri Williams5,
  6. Astha Soni1,
  7. Alison Timmis6,
  8. Melanie Kershaw7,
  9. Josephine Drew8,
  10. Christopher Moudiotis9,
  11. Sze May Ng10,11
  12. On behalf of the Association of Children’s Diabetes Clinicians UK
  1. 1 Sheffield Children's NHS Foundation Trust, Sheffield, UK
  2. 2 Wexham Park Hospital, Slough, UK
  3. 3 Department of Paediatrics, Sandwell and West Birmingham NHS Trust, West Bromwich, UK
  4. 4 Institute of Clinical Sciences, College of Medicine and Dental Sciences, University of Birmingham, Birmingham, UK
  5. 5 Hampshire Hospitals NHS Foundation Trust, Winchester, UK
  6. 6 Countess of Chester Hospital NHS Foundation Trust, Chester, UK
  7. 7 Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK
  8. 8 Department of Paediatrics, Nottingham University Hospitals NHS Trust, Nottingham, UK
  9. 9 Department of Paediatrics, Royal Devon and Exeter NHs Foundation Trust, Exeter, UK
  10. 10 Paediatric Department, Southport and Ormskirk NHS Trust, Ormskirk, UK
  11. 11 Department of Women's and Children's Health, University of Liverpool, Liverpool, UK
  1. Correspondence to Dr Sze May Ng, Paediatric Department, Southport and Ormskirk NHS Trust, Ormskirk L39 2AZ, UK;{at}

Statistics from

We write to report on the Association of Children’s Diabetes Clinicians’ (ACDC) national survey on access to continuous glucose monitoring (CGM) and Freestyle Libre Flash Glucose Sensors (FGS) for children and young people (CYP) with type 1 diabetes (T1DM) in England and Wales.

CGM and FGS allow continuous blood glucose monitoring for patients with T1DM, therefore reducing the need for finger-prick blood testing. CGM provides a continuous interstitial glucose reading, whereas FGS requires 8 hourly scans to provide data with no alarms.

Funding pathways for such devices are complex. While there is clear guidance from The National Institute of Health and Care Excellence (NICE) with regards to whom CGM should be prescribed,1 access is determined locally by Clinical Commissioning Groups (CCGs). Some CCGs require individual funding applications (IFAs), whereas others have local policies on who should access devices. The recently published National Health Service (NHS) Long-Term Plan, advises that all individuals meeting published clinical criteria should be able to access FGS devices from April …

View Full Text


  • Collaborators On behalf of the Association of Children’s Diabetes Clinicians, UK.

  • Contributors This work was conducted on behalf of the Association of Children’s Diabetes Clinicians. UK. The concept for the survey was developed by the authors. ECF initially drafted the survey which was developed and approved by all the authors. ECF analysed the data and ECF and MN drafted the paper which was edited and approved by all the authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.